Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.
The deal would be the second-largest privatisation of a US-listed Chinese company and could pave the way for a relisting in China or Hong Kong if completed.